Candidatus Mycoplasma haemohominis in Human, Japan
Norimichi Hattori
1 , Makoto Kuroda
1, Harutaka Katano
1, Takahiro Takuma
1, Takayoshi Ito
1, Nana Arai, Ryo Yanai, Tsuyoshi Sekizuka, Sho Ishii, Yoko Miura, Takahiro Tokunaga, Hiroyuki Watanabe, Norihiro Nomura, Junichi Eguchi, Hideki Hasegawa, Tsuyoshi Nakamaki, Takaji Wakita, and Yoshihito Niki
Author affiliations: Showa University School of Medicine, Tokyo, Japan (N. Hattori, T. Takuma, N. Arai, R. Yanai, S. Ishii, Y. Miura, T. Tokunaga, T. Nakamaki, Y. Niki); National Institute of Infectious Diseases, Tokyo (M. Kuroda, H. Katano, T. Sekizuka, H. Hasegawa, T. Wakita); Showa Uuniversity Koto Toyosu Hospital, Tokyo (T. Ito, H. Watanabe, N. Nomura, J. Eguchi)
Main Article
Figure 2
Figure 2. Clinical course for a 42-year-old man infected with Candidatus Mycoplasma haemohominis, Japan. *For ALT, AST, and LDH, left y-axis is for AST and ALT and right y-axis is for LDH. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; DEX, dexamethasone; Hb, hemoglobin; LDH, lactate dehydrogenase; LVFX, levofloxacin; MINO, minocycline; MLFX, moxifloxacin; mPSL, methylprednisolone; PLT, platelets; STFX, sitafloxacin; WBC, white blood cells.
Main Article
Page created: December 18, 2019
Page updated: December 18, 2019
Page reviewed: December 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.